Drug Profile

129 Xenon - Polarean Imaging

Alternative Names: 129Xe-MRI; 129Xenon-MRI; Xenon Xe 129 hyperpolarized; XENOVIEW

Latest Information Update: 11 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator GE Healthcare
Developer Polarean Imaging
Class Diagnostic agents; Imaging agents
Mechanism of Action Magnetic resonance imaging enhancers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Lung disorders

Most Recent Events

02 Jun 2025 Launched for Lung disorders (Diagnosis, In children) in USA (Inhalation)
02 Jun 2025 Registered for Lung disorders (Diagnosis, In children) in USA (Inhalation)
08 Sep 2023 Polarean Imaging partnered with VIDA Diagnostics to develop solutions that further enable the Polarean xenon 129 MRI platform to accelerate clinical and research use.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com